ReNeuron Group company
ReNeuron Group Plc engages in the research, development, and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.
It develops stem cell therapies for a range of neurodegenerative diseases and other conditions, including Parkinson's disease, Type 1 diabetes, and diseases of the retina. The company's therapeutic product pipeline includes ReN001, a pre-clinical development stage therapy for disabled stroke patients. Its other therapeutic and non-therapeutic programs in pre-clinical trials comprise ReN002 for diabetes, ReN003 for retinal diseases, ReN004 for Parkinson's disease, and ReN005 for Huntington's disease. ReNeuron Group also develops and markets neural stem cell lines that include ReNcell VM and ReNcell CX.
The company was founded in 1997 and is headquartered in Guildford, the United Kingdom.
It develops stem cell therapies for a range of neurodegenerative diseases and other conditions, including Parkinson's disease, Type 1 diabetes, and diseases of the retina. The company's therapeutic product pipeline includes ReN001, a pre-clinical development stage therapy for disabled stroke patients. Its other therapeutic and non-therapeutic programs in pre-clinical trials comprise ReN002 for diabetes, ReN003 for retinal diseases, ReN004 for Parkinson's disease, and ReN005 for Huntington's disease. ReNeuron Group also develops and markets neural stem cell lines that include ReNcell VM and ReNcell CX.
The company was founded in 1997 and is headquartered in Guildford, the United Kingdom.
.jpg)
.jpg)
Technology:
Regenerative Medicine
Industry:
Regenerative Medicine
Headquarters:
Guildford, Surrey, United Kingdom
Founded Date:
6-19
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
4
Total Funding:
$167.3M
Estimated Revenue:
$1M to $10M
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership